SCHEMBL1581973

SCHEMBL1581973

CCOC(=O)/C(=C/CCC(C)C)c1ccc(SC)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 4/20 0.44
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
LMNA P02545 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 2/20 0.39
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.37
AKR1C3 P42330 3/20 0.36
AKR1C2 P52895 2/20 0.36
AKR1C1 Q04828 2/20 0.36
HRH2 P25021 1/20 0.35
HRH1 P35367 1/20 0.35
PLK1 P53350 1/20 0.35
RCE1 Q9Y256 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1581975 1.00 MAPT (0.44) MAPTALDH1A1KDM4ETAS1R3TAS1R1
SCHEMBL1582170 0.87 MAPT (0.46) MAPTALDH1A1KDM4ETAS1R3TAS1R1
SCHEMBL1582168 0.87 MAPT (0.46) MAPTALDH1A1KDM4ETAS1R3TAS1R1
SCHEMBL1582184 0.81 MAPT (0.48) MAPTALDH1A1KDM4ETAS1R3TAS1R1
SCHEMBL1582057 0.81 AKR1C3 (0.41) ALDH1A1AKR1C3
SCHEMBL1582055 0.81 AKR1C3 (0.41) ALDH1A1AKR1C3
SCHEMBL1582071 0.79 MAPT (0.46) MAPTALDH1A1KDM4ETAS1R3TAS1R1
SCHEMBL1582067 0.79 MAPT (0.46) MAPTALDH1A1KDM4ETAS1R3TAS1R1
SCHEMBL1581875 0.74 ALDH1A1 (0.42) MAPTALDH1A1KDM4ELMNANPSR1
SCHEMBL1581872 0.74 ALDH1A1 (0.42) MAPTALDH1A1KDM4ELMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 MAPT 4102/4885ALDH1A1 510/4885KDM4E 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.